Exosomes for neurodegenerative diseases: diagnosis and targeted therapy

1.

Erkkinen MG, Kim MO, Geschwind MD (2018) Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol 10(4):a033118. https://doi.org/10.1101/cshperspect.a033118CrossRefPubMedPubMedCentral

2.

Wright BL, Lai JT, Sinclair AJ (2012) Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol 259(8):1530–1545. https://doi.org/10.1007/s00415-012-6413-xCrossRefPubMed

3.

Dong X (2018) Current strategies for brain drug delivery. Theranostics 8(6):1481–1493. https://doi.org/10.7150/thno.21254CrossRefPubMedPubMedCentral

4.

Thomsen MS, Humle N, Hede E, Moos T, Burkhart A, Thomsen LB (2021) The blood-brain barrier studied in vitro across species. PLoS One 16(3):e0236770. https://doi.org/10.1371/journal.pone.0236770CrossRefPubMedPubMedCentral

5.

Gray SJ, Woodard KT, Samulski RJ (2010) Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv 1(4):517–534. https://doi.org/10.4155/tde.10.50CrossRefPubMed

6.

Vagner T, Dvorzhak A, Wójtowicz AM, Harms C, Grantyn R (2016) Systemic application of AAV vectors targeting GFAP-expressing astrocytes in Z-Q175-KI Huntington’s disease mice. Mol Cell Neurosci 77:76–86. https://doi.org/10.1016/j.mcn.2016.10.007CrossRefPubMed

7.

Wohlfart S, Gelperina S, Kreuter J (2012) Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 161(2):264–273. https://doi.org/10.1016/j.jconrel.2011.08.017CrossRefPubMed

8.

Kreuter J (2013) Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB). J Microencapsul 30(1):49–54. https://doi.org/10.3109/02652048.2012.692491CrossRefPubMed

9.

Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 235:34–47. https://doi.org/10.1016/j.jconrel.2016.05.044CrossRefPubMed

10.

Pinheiro RGR, Coutinho AJ, Pinheiro M, Neves AR (2021) Nanoparticles for targeted brain drug delivery: what do we know? Int J Mol Sci 22(21):11654. https://doi.org/10.3390/ijms222111654CrossRefPubMedPubMedCentral

11.

Ogawa K, Kato N, Yoshida M, Hiu T, Matsuo T, Mizukami S, Omata D, Suzuki R, Maruyama K, Mukai H, Kawakami S (2022) Focused ultrasound/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain. J Control Release 348:34–41. https://doi.org/10.1016/j.jconrel.2022.05.042CrossRefPubMed

12.

Chu C, Jablonska A, Lesniak WG, Thomas AM, Lan X, Linville RM, Li S, Searson PC, Liu G, Pearl M, Pomper MG, Janowski M, Magnus T, Walczak P (2020) Optimization of osmotic blood-brain barrier opening to enable intravital microscopy studies on drug delivery in mouse cortex. J Control Release 317:312–321. https://doi.org/10.1016/j.jconrel.2019.11.019CrossRefPubMed

13.

Bhattamisra SK, Shak AT, Xi LW, Safian NH, Choudhury H, Lim WM, Shahzad N, Alhakamy NA, Anwer MK, Radhakrishnan AK, Md S (2020) Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease. Int J Pharm 579:119148. https://doi.org/10.1016/j.ijpharm.2020.119148CrossRefPubMed

14.

Kashyap K, Shukla R (2019) Drug delivery and targeting to the brain through nasal route: mechanisms. Appl Challenges Curr Drug Deliv 16(10):887–901. https://doi.org/10.2174/1567201816666191029122740CrossRef

15.

Harding C, Heuser J, Stahl P (1983) Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 97(2):329–339. https://doi.org/10.1083/jcb.97.2.329CrossRefPubMed

16.

Kalluri R, LeBleu VS (2020) The biology, function, and biomedical applications of exosomes. Science. https://doi.org/10.1126/science.aau6977CrossRefPubMedPubMedCentral

17.

Rastogi S, Sharma V, Bharti PS, Rani K, Modi GP, Nikolajeff F, Kumar S (2021) The evolving landscape of exosomes in neurodegenerative diseases: exosomes characteristics and a promising role in early diagnosis. Int J Mol Sci 22(1):440. https://doi.org/10.3390/ijms22010440CrossRefPubMedPubMedCentral

18.

Fan Y, Chen Z, Zhang M (2022) Role of exosomes in the pathogenesis, diagnosis, and treatment of central nervous system diseases. J Transl Med 20(1):291. https://doi.org/10.1186/s12967-022-03493-6CrossRefPubMedPubMedCentral

19.

Doyle LM, Wang MZ (2019) Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells 8(7):727. https://doi.org/10.3390/cells8070727CrossRefPubMedPubMedCentral

20.

Fuhrmann G, Herrmann IK, Stevens MM (2015) Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today 10(3):397–409. https://doi.org/10.1016/j.nantod.2015.04.004CrossRefPubMedPubMedCentral

21.

Rehman FU, Liu Y, Zheng M, Shi B (2023) Exosomes based strategies for brain drug delivery. Biomaterials 293:121949. https://doi.org/10.1016/j.biomaterials.2022.121949CrossRefPubMed

22.

van Niel G, D’Angelo G, Raposo G (2018) Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19(4):213–228. https://doi.org/10.1038/nrm.2017.125CrossRefPubMed

23.

Properzi F, Ferroni E, Poleggi A, Vinci R (2015) The regulation of exosome function in the CNS: implications for neurodegeneration. Swiss Med Wkly 145:w14204. https://doi.org/10.4414/smw.2015.14204CrossRefPubMed

24.

Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, Zanesi N, Crawford M, Ozer GH, Wernicke D, Alder H, Caligiuri MA, Nana-Sinkam P, Perrotti D, Croce CM (2012) MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 109(31):E2110–E2116. https://doi.org/10.1073/pnas.1209414109CrossRefPubMedPubMedCentral

25.

Ha D, Yang N, Nadithe V (2016) Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 6(4):287–96. https://doi.org/10.1016/j.apsb.2016.02.001CrossRefPubMedPubMedCentral

26.

Liang Y, Duan L, Lu J, Xia J (2021) Engineering exosomes for targeted drug delivery. Theranostics 11(7):3183–3195. https://doi.org/10.7150/thno.52570CrossRefPubMedPubMedCentral

27.

Xu M, Feng T, Liu B, Qiu F, Xu Y, Zhao Y, Zheng Y (2021) Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies. Theranostics 11(18):8926–8944. https://doi.org/10.7150/thno.62330CrossRefPubMedPubMedCentral

28.

Chen H, Wang L, Zeng X, Schwarz H, Nanda HS, Peng X, Zhou Y (2021) Exosomes, a new star for targeted delivery. Front Cell Dev Biol 9:751079. https://doi.org/10.3389/fcell.2021.751079CrossRefPubMedPubMedCentral

29.

Fu S, Wang Y, Xia X, Zheng JC (2020) Exosome engineering: Current progress in cargo loading and targeted delivery. Nanoimpact 20:100261. https://doi.org/10.1016/j.impact.2020.100261CrossRef

30.

Kimiz-Gebologlu I, Oncel SS (2022) Exosomes: Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J Control Release 347:533–543. https://doi.org/10.1016/j.jconrel.2022.05.027CrossRefPubMed

31.

He R, Jiang Y, Shi Y, Liang J, Zhao L (2020) Curcumin-laden exosomes target ischemic brain tissue and alleviate cerebral ischemia-reperfusion injury by inhibiting ROS-mediated mitochondrial apoptosis. Mater Sci Eng C Mater Biol Appl 117:111314. https://doi.org/10.1016/j.msec.2020.111314CrossRefPubMed

32.

Altanerova U, Babincova M, Babinec P, Benejova K, Jakubechova J, Altanerova V, Zduriencikova M, Repiska V, Altaner C (2017) Human mesenchymal stem cell-derived iron oxide exosomes allow targeted ablation of tumor cells via magnetic hyperthermia. Int J Nanomedicine 12:7923–7936. https://doi.org/10.2147/IJN.S145096CrossRefPubMedPubMedCentral

33.

Ge X, Guo M, Hu T, Li W, Huang S, Yin Z, Li Y, Chen F, Zhu L, Kang C, Jiang R, Lei P, Zhang J (2020) Increased microglial exosomal miR-124-3p alleviates neurodegeneration and improves cognitive outcome after rmTBI. Mol Ther 28(2):503–522. https://doi.org/10.1016/j.ymthe.2019.11.017CrossRefPubMed

34.

Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y (2016) Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials 111:55–65. https://doi.org/10.1016/j.biomaterials.2016.09.031CrossRefPubMed

35.

Qu M, Lin Q, Huang L, Fu Y, Wang L, He S, Fu Y, Yang S, Zhang Z, Zhang L, Sun X (2018) Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease. J Control Release 287:156–166. https://doi.org/10.1016/j.jconrel.2018.08.035CrossRefPubMed

36.

Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, Patel T, Piroyan A, Sokolsky M, Kabanov AV, Batrakova EV (2015) Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Control Release 207:18–30. https://doi.org/10.1016/j.jconrel.2015.03.033CrossRefPubMedPubMedCentral

37.

Qi H, Liu C, Long L, Ren Y, Zhang S, Chang X, Qian X, Jia H, Zhao J, Sun J, Hou X, Yuan X, Kang C (2016) Blood exosomes endowed with magnetic and targeting properties for cancer therapy. ACS Nano 10(3):3323–3333. https://doi.org/10.1021/acsnano.5b06939CrossRefPubMed

38.

Gong C, Tian J, Wang Z, Gao Y, Wu X, Ding X, Qiang L, Li G, Han Z, Yuan Y, Gao S (2019) Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. J Nanobiotechnology 17(1):93. https://doi.org/10.1186/s12951-019-0526-7CrossRefPubMedPubMedCentral

39.

Gunassekaran GR, Poongkavithai Vadevoo SM, Baek MC, Lee B (2021) M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials 278:121137. https://doi.org/10.1016/j.biomaterials.2021.121137CrossRefPubMed

40.

Kumar DN, Chaudhuri A, Kumar D, Singh S, Agrawal AK (2023) Impact of the drug loading method on the drug distribution and biological efficacy of exosomes. AAPS PharmSciTech 24(6):166. https://doi.org/10.1208/s12249-023-02624-6CrossRefPubMed

41.

Sancho-Albero M, Encabo-Berzosa MDM, Beltrán-Visiedo M, Fernández-Messina L, Sebastián V, Sánchez-Madrid F, Arruebo M, Santamaría J, Martín-Duque P (2019) Efficient encapsulation of theranostic nanoparticles in cell-derived exosomes: leveraging the exosomal biogenesis pathway to obtain hollow gold nanoparticle-hybrids. Nanoscale. 11(40):18825–18836. https://doi.org/10.1039/C9NR06183ECrossRefPubMed

42.

Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O, Hingtgen SD, Kabanov AV, Batrakova EV (2016) Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12(3):655–664. https://doi.org/10.1016/j.nano.2015.10.012CrossRefPubMed

43.

Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29(4):341–345. https://doi.org/10.1038/nbt.1807CrossRefPubMed

44.

Park O, Choi ES, Yu G, Kim JY, Kang YY, Jung H, Mok H (2018) Efficient delivery of tyrosinase related protein-2 (TRP2) peptides to lymph nodes using serum-derived exosomes. Macromol Biosci 18(12):e1800301. https://doi.org/10.1002/mabi.201800301CrossRefPubMed

45.

Pan S, Pei L, Zhang A, Zhang Y, Zhang C, Huang M, Huang Z, Liu B, Wang L, Ma L, Zhang Q, Cui D (2020) Passion fruit-like exosome-PMA/Au-BSA@Ce6 nanovehicles for real-time fluorescence imaging and enhanced targeted photodynamic therapy with deep penetration and superior retention behavior in tumor. Biomaterials 230:119606. https://doi.org/10.1016/j.biomaterials.2019.119606CrossRefPubMed

46.

Fuhrmann G, Serio A, Mazo M, Nair R, Stevens MM (2015) Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J Control Release 205:35–44. https://doi.org/10.1016/j.jconrel.2014.11.029CrossRefPubMed

47.

Jeyaram A, Lamichhane TN, Wang S, Zou L, Dahal E, Kronstadt SM, Levy D, Parajuli B, Knudsen DR, Chao W, Jay SM (2020) Enhanced loading of functional miRNA cargo via pH gradient modification of extracellular vesicles. Mol Ther 28(3):975–985. https://doi.org/10.1016/j.ymthe.2019.12.007CrossRefPubMed

48.

Gao J, Wang S, Wang Z (2017) High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy. Biomaterials 135:62–73. https://doi.org/10.1016/j.biomaterials.2017.05.003CrossRefPubMedPubMedCentral

49.

Luarte A, Bátiz LF, Wyneken U, Lafourcade C (2016) Potential therapies by stem cell-derived exosomes in CNS diseases: focusing on the neurogenic niche. Stem Cells Int 2016:5736059. https://doi.org/10.1155/2016/5736059CrossRefPubMedPubMedCentral

50.

Yu Y, Li W, Mao L, Peng W, Long D, Li D, Zhou R, Dang X (2021) Genetically engineered exosomes display RVG peptide and selectively enrich a neprilysin variant: a potential formulation for the treatment of Alzheimer’s disease. J Drug Target 29(10):1128–1138. https://doi.org/10.1080/1061186X.2021.1929257CrossRefPubMed

51.

Cooper JM, Wiklander PB, Nordin JZ, Al-Shawi R, Wood MJ, Vithlani M, Schapira AH, Simons JP, El-Andaloussi S, Alvarez-Erviti L (2014) Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord 29(12):1476–1485. https://doi.org/10.1002/mds.25978CrossRefPubMedPubMedCentral

52.

Phoolcharoen W, Prehaud C, van Dolleweerd CJ, Both L, da Costa A, Lafon M, Ma JK (2017) Enhanced transport of plant-produced rabies single-chain antibody-RVG peptide fusion protein across an in cellulo blood-brain barrier device. Plant Biotechnol J 15(10):1331–1339. https://doi.org/10.1111/pbi.12719CrossRefPubMedPubMedCentral

53.

Liang G, Kan S, Zhu Y, Feng S, Feng W, Gao S (2018) Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells. Int J Nanomed 13:585–599. https://doi.org/10.2147/IJN.S154458CrossRef

54.

Cheng Q, Shi X, Han M, Smbatyan G, Lenz HJ, Zhang Y (2018) Reprogramming exosomes as nanoscale controllers of cellular immunity. J Am Chem Soc 140(48):16413–16417. https://doi.org/10.1021/jacs.8b10047CrossRefPubMedPubMedCentral

55.

Longatti A, Schindler C, Collinson A, Jenkinson L, Matthews C, Fitzpatrick L, Blundy M, Minter R, Vaughan T, Shaw M, Tigue N (2018) High affinity single-chain variable fragments are specific and versatile targeting motifs for extracellular vesicles. Nanoscale 10(29):14230–14244. https://doi.org/10.1039/c8nr03970dCrossRefPubMed

56.

Kooijmans SA, Aleza CG, Roffler SR, van Solinge WW, Vader P, Schiffelers RM (2016) Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. J Extracell Vesicles 5:31053. https://doi.org/10.3402/jev.v5.31053CrossRefPubMed

57.

Tian T, Zhang HX, He CP, Fan S, Zhu YL, Qi C, Huang NP, Xiao ZD, Lu ZH, Tannous BA, Gao J (2018) Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials 150:137–149. https://doi.org/10.1016/j.biomaterials.2017.10.012CrossRefPubMed

58.

Cui GH, Guo HD, Li H, Zhai Y, Gong ZB, Wu J, Liu JS, Dong YR, Hou SX, Liu JR (2019) RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer’s disease. Immun Ageing 16:10. https://doi.org/10.1186/s12979-019-0150-2CrossRefPubMedPubMedCentral

59.

Hosseini Shamili F, Alibolandi M, Rafatpanah H, Abnous K, Mahmoudi M, Kalantari M, Taghdisi SM, Ramezani M (2019) Immunomodulatory properties of MSC-derived exosomes armed with high affinity aptamer toward mylein as a platform for reducing multiple sclerosis clinical score. J Control Release 299:149–164. https://doi.org/10.1016/j.jconrel.2019.02.032CrossRefPubMed

60.

Hwang DW, Jo MJ, Lee JH, Kang H, Bao K, Hu S, Baek Y, Moon HG, Lee DS, Kashiwagi S, Henary M, Choi HS (2019) Chemical modulation of bioengineered exosomes for tissue-specific biodistribution. Adv Ther (Weinh) 2(11):1900111. https://doi.org/10.1002/adtp.201900111CrossRefPubMed

61.

Liu L, Li Y, Peng H, Liu R, Ji W, Shi Z, Shen J, Ma G, Zhang X (2020) Targeted exosome coating gene-chem nanocomplex as “nanoscavenger” for clearing α-synuclein and immune activation of Parkinson’s disease. Sci Adv. https://doi.org/10.1126/sciadv.aba3967CrossRefPubMedPubMedCentral

62.

Han M, Xing H, Chen L, Cui M, Zhang Y, Qi L, Jin M, Yang Y, Gao C, Gao Z, Xing X, Huang W (2021) Efficient antiglioblastoma therapy in mice through doxorubicin-loaded nanomicelles modified using a novel brain-targeted RVG-15 peptide. J Drug Target 29(9):1016–1028. https://doi.org/10.1080/1061186X.2021.1912053CrossRefPubMed

63.

Lin Y, Wu J, Gu W, Huang Y, Tong Z, Huang L, Tan J (2018) Exosome-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs. Adv Sci (Weinh) 5(4):1700611. https://doi.org/10.1002/advs.201700611CrossRefPubMed

64.

Zhuang M, Du D, Pu L, Song H, Deng M, Long Q, Yin X, Wang Y, Rao L (2019) SPION-decorated exosome delivered BAY55-9837 TARGETING the pancreas through magnetism to improve the blood GLC response. Small 15(52):e1903135. https://doi.org/10.1002/smll.201903135CrossRefPubMed

65.

Jia G, Han Y, An Y, Ding Y, He C, Wang X, Tang Q (2018) NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo. Biomaterials 178:302–316. https://doi.org/10.1016/j.biomaterials.2018.06.029CrossRefPubMed

66.

Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, Abner EL, Petersen RC, Federoff HJ, Miller BL, Goetzl EJ (2015) Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement 11(6):600–7.e1. https://doi.org/10.1016/j.jalz.2014.06.008CrossRefPubMed

67.

Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, Masliah E, Rissman RA (2016) Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement (Amst) 3:63–72. https://doi.org/10.1016/j.dadm.2016.04.001CrossRefPubMed

68.

Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J, Zhou C, Liang F, Shi S, Wang S, Qin W, Wang Q, Li F, Wang Q, Li Y, Shen L, Wei Y, Jia J (2019) Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement 15(8):1071–1080. https://doi.org/10.1016/j.jalz.2019.05.002CrossRefPubMed

69.

Goetzl EJ, Mustapic M, Kapogiannis D, Eitan E, Lobach IV, Goetzl L, Schwartz JB, Miller BL (2016) Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer’s disease. FASEB J 30(11):3853–3859. https://doi.org/10.1096/fj.201600756RCrossRefPubMedPubMedCentral

70.

Arioz BI, Tufekci KU, Olcum M, Durur DY, Akarlar BA, Ozlu N, Bagriyanik HA, Keskinoglu P, Yener G, Genc S (2021) Proteome profiling of neuron-derived exosomes in Alzheimer’s disease reveals hemoglobin as a potential biomarker. Neurosci Lett 755:135914. https://doi.org/10.1016/j.neulet.2021.135914CrossRefPubMed

71.

Goetzl EJ, Boxer A, Schwartz JB, Abner EL, Petersen RC, Miller BL, Kapogiannis D (2015) Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology 85(1):40–47. https://doi.org/10.1212/WNL.0000000000001702CrossRefPubMedPubMedCentral

72.

Krishna G, Kn A, Kumar RS, Sagar BC, Philip M, Dahale AB, Issac TG, Mukku SSR, Sivakumar PT, Subramanian S (2020) Higher levels of lysosomal associated membrane protein-2 (LAMP-2) in plasma exosomes from Alzheimer’s disease: an exploratory study from South India. Asian J Psychiatr 48:101898. https://doi.org/10.1016/j.ajp.2019.101898CrossRefPubMed

73.

Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL, Jicha GA, Karydas AM, Boxer A, Miller BL (2016) Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease. FASEB J 30(12):4141–4148. https://doi.org/10.1096/fj.201600816RCrossRefPubMedPubMedCentral

74.

Agliardi C, Guerini FR, Zanzottera M, Bianchi A, Nemni R, Clerici M (2019) SNAP-25 in serum is carried by exosomes of neuronal origin and is a potential biomarker of Alzheimer’s disease. Mol Neurobiol 56(8):5792–5798. https://doi.org/10.1007/s12035-019-1501-xCrossRefPubMed

75.

Cai H, Pang Y, Wang Q, Qin W, Wei C, Li Y, Li T, Li F, Wang Q, Li Y, Wei Y, Jia L (2022) Proteomic profiling of circulating plasma exosomes reveals novel biomarkers of Alzheimer’s disease. Alzheimers Res Ther 14(1):181. https://doi.org/10.1186/s13195-022-01133-1CrossRefPubMedPubMedCentral

76.

Kumar P, Dezso Z, MacKenzie C, Oestreicher J, Agoulnik S, Byrne M, Bernier F, Yanagimachi M, Aoshima K, Oda Y (2013) Circulating miRNA biomarkers for Alzheimer’s disease. PLoS ONE 8(7):e69807. https://doi.org/10.1371/journal.pone.0069807CrossRefPubMedPubMedCentral

77.

Lugli G, Cohen AM, Bennett DA, Shah RC, Fields CJ, Hernandez AG, Smalheiser NR (2015) Plasma exosomal miRNAs in persons with and without Alzheimer disease: altered expression and prospects for biomarkers. PLoS One 10(10):e0139233. https://doi.org/10.1371/journal.pone.0139233CrossRefPubMedPubMedCentral

78.

Gámez-Valero A, Campdelacreu J, Vilas D, Ispierto L, Reñé R, Álvarez R, Armengol MP, Borràs FE, Beyer K (2019) Exploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimer’s disease and dementia with Lewy bodies. Transl Neurodegener 8:31. https://doi.org/10.1186/s40035-019-0169-5CrossRefPubMedPubMedCentral

79.

Cha DJ, Mengel D, Mustapic M, Liu W, Selkoe DJ, Kapogiannis D, Galasko D, Rissman RA, Bennett DA, Walsh DM (2019) miR-212 and miR-132 are downregulated in neurally derived plasma exosomes of Alzheimer’s patients. Front Neurosci 13:1208. https://doi.org/10.3389/fnins.2019.01208CrossRefPubMedPubMedCentral

80.

Serpente M, Fenoglio C, D’Anca M, Arcaro M, Sorrentino F, Visconte C, Arighi A, Fumagalli GG, Porretti L, Cattaneo A, Ciani M, Zanardini R, Benussi L, Ghidoni R, Scarpini E, Galimberti D (2020) MiRNA profiling in plasma neural-derived small extracellular vesicles from patients with Alzheimer’s disease. Cells 9(6):1443. https://doi.org/10.3390/cells9061443CrossRefPubMedPubMedCentral

81.

Dong Z, Gu H, Guo Q, Liang S, Xue J, Yao F, Liu X, Li F, Liu H, Sun L, Zhao K (2021) Profiling of serum exosome MiRNA reveals the potential of a MiRNA panel as diagnostic biomarker for Alzheimer’s disease. Mol Neurobiol 58(7):3084–3094. https://doi.org/10.1007/s12035-021-02323-yCrossRefPubMed

82.

Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC (2018) The serum exosome derived MicroRNA-135a, -193b, and -384 were potential Alzheimer’s disease biomarkers. Biomed Environ Sci 31(2):87–96. https://doi.org/10.3967/bes2018.011CrossRefPubMed

83.

Taşdelen E, Özel Kızıl ET, Tezcan S, Yalap E, Bingöl AP, Kutlay NY (2022) Determination of miR-373 and miR-204 levels in neuronal exosomes in Alzheimer’s disease. Turk J Med Sci. 52(5):1458–1467. https://doi.org/10.55730/1300-0144.5484

84.

Rani K, Rastogi S, Vishwakarma P, Bharti PS, Sharma V, Renu K, Modi GP, Vishnu VY, Chatterjee P, Dey AB, Nikolajeff F, Kumar S (2021) A novel approach to correlate the salivary exosomes and their protein cargo in the progression of cognitive impairment into Alzheimer’s disease. J Neurosci Methods 347:108980. https://doi.org/10.1016/j.jneumeth.2020.108980CrossRefPubMed

85.

Sun R, Wang H, Shi Y, Gao D, Sun Z, Chen Z, Jiang H, Zhang J (2019) A pilot study of urinary exosomes in Alzheimer’s disease. Neurodegener Dis 19(5–6):184–191. https://doi.org/10.1159/000505851CrossRefPubMed

86.

Jiang C, Hopfner F, Katsikoudi A, Hein R, Catli C, Evetts S, Huang Y, Wang H, Ryder JW, Kuhlenbaeumer G, Deuschl G, Padovani A, Berg D, Borroni B, Hu MT, Davis JJ, Tofaris GK (2020) Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical Parkinsonism. J Neurol Neurosurg Psychiatry 91(7):720–729. https://doi.org/10.1136/jnnp-2019-322588CrossRefPubMed

87.

Niu M, Li Y, Li G, Zhou L, Luo N, Yao M, Kang W, Liu J (2020) A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson’s disease development and progression. Eur J Neurol 27(6):967–974. https://doi.org/10.1111/ene.14208CrossRefPubMed

88.

Jiang C, Hopfner F, Berg D, Hu MT, Pilotto A, Borroni B, Davis JJ, Tofaris GK (2021) Validation of α-synuclein in L1CAM-immunocaptured exosomes as a biomarker for the stratification of Parkinsonian syndromes. Mov Disord 36(11):2663–2669. https://doi.org/10.1002/mds.28591CrossRefPubMedPubMedCentral

89.

Zhao ZH, Chen ZT, Zhou RL, Zhang X, Ye QY, Wang YZ (2019) Increased DJ-1 and α-synuclein in plasma neural-derived exosomes as potential markers for Parkinson’s disease. Front Aging Neurosci 10:438. https://doi.org/10.3389/fnagi.2018.00438CrossRefPubMedPubMedCentral

90.

Zou J, Guo Y, Wei L, Yu F, Yu B, Xu A (2020) Long noncoding RNA POU3F3 and α-synuclein in plasma L1CAM exosomes combined with β-Glucocerebrosidase activity: potential predictors of Parkinson’s disease. Neurotherapeutics 17(3):1104–1119. https://doi.org/10.1007/s13311-020-00842-5CrossRefPubMedPubMedCentral

91.

Dutta S, Hornung S, Kruayatidee A, Maina KN, Del Rosario I, Paul KC, Wong DY, Duarte Folle A, Markovic D, Palma JA, Serrano GE, Adler CH, Perlman SL, Poon WW, Kang UJ, Alcalay RN, Sklerov M, Gylys KH, Kaufmann H, Fogel BL, Bronstein JM, Ritz B, Bitan G (2021) α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson’s disease from multiple system atrophy. Acta Neuropathol 142(3):495–511. https://doi.org/10.1007/s00401-021-02324-0CrossRefPubMedPubMedCentral

92.

Shi M, Kovac A, Korff A, Cook TJ, Ginghina C, Bullock KM, Yang L, Stewart T, Zheng D, Aro P, Atik A, Kerr KF, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Montine TJ, Banks WA, Zhang J (2016) CNS tau efflux via exosomes is likely increased in Parkinson’s disease but not in Alzheimer’s disease. Alzheimers Dement 12(11):1125–1131. https://doi.org/10.1016/j.jalz.2016.04.003CrossRefPubMed

93.

Kitamura Y, Kojima M, Kurosawa T, Sasaki R, Ichihara S, Hiraku Y, Tomimoto H, Murata M, Oikawa S (2018) Proteomic profiling of exosomal proteins for blood-based biomarkers in Parkinson’s disease. Neuroscience 392:121–128. https://doi.org/10.1016/j.neuroscience.2018.09.017CrossRefPubMed

94.

Jiang R, Rong C, Ke R, Meng S, Yan X, Ke H, Wu S (2019) Differential proteomic analysis of serum exosomes reveals alterations in progression of Parkinson disease. Medicine (Baltimore) 98(41):e17478. https://doi.org/10.1097/MD.0000000000017478CrossRefPubMed

95.

Shim KH, Go HG, Bae H, Jeong DE, Kim D, Youn YC, Kim S, An SSA, Kang MJ (2021) Decreased exosomal acetylcholinesterase activity in the plasma of patients with Parkinson’s disease. Front Aging Neurosci 13:665400. https://doi.org/10.3389/fnagi.2021.665400CrossRefPubMedPubMedCentral

96.

Chen ZT, Pan CZ, Ruan XL, Lei LP, Lin SM, Wang YZ, Zhao ZH (2023) Evaluation of ferritin and TfR level in plasma neural-derived exosomes as potential markers of Parkinson’s disease. Front Aging Neurosci 15:1216905. https://doi.org/10.3389/fnagi.2023.1216905CrossRefPubMedPubMedCentral

97.

Cao XY, Lu JM, Zhao ZQ, Li MC, Lu T, An XS, Xue LJ (2017) MicroRNA biomarkers of Parkinson’s disease in serum exosome-like microvesicles. Neurosci Lett 644:94–99. https://doi.org/10.1016/j.neulet.2017.02.045CrossRefPubMed

98.

Yao YF, Qu MW, Li GC, Zhang FB, Rui HC (2018) Circulating exosomal miRNAs as diagnostic biomarkers in Parkinson’s disease. Eur Rev Med Pharmacol Sci 22(16):5278–5283. https://doi.org/10.26355/eurrev_201808_15727

99.

He S, Huang L, Shao C, Nie T, Xia L, Cui B, Lu F, Zhu L, Chen B, Yang Q (2021) Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease. Transl Neurodegener 10(1):25. https://doi.org/10.1186/s40035-021-00249-yCrossRefPubMedPubMedCentral

100.

Grossi I, Radeghieri A, Paolini L, Porrini V, Pilotto A, Padovani A, Marengoni A, Barbon A, Bellucci A, Pizzi M, Salvi A, De Petro G (2021) MicroRNA-34a-5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson’s disease: an exploratory study. Int J Mol Med 47(2):533–546. https://doi.org/10.3892/ijmm.2020.4806CrossRefPubMed

101.

Tong G, Zhang P, Hu W, Zhang K, Chen X (2022) Diagnostic test to identify Parkinson’s disease from the blood sera of Chinese population: a cross-sectional study. Parkinsons Dis 2022:8683877. https://doi.org/10.1155/2022/8683877CrossRefPubMedPubMedCentral

102.

Bhattacharyya P, Biswas A, Biswas SC (2023) Brain-enriched miR-128: reduced in exosomes from Parkinson’s patient plasma, improves synaptic integrity, and prevents 6-OHDA mediated neuronal apoptosis. Front Cell Neurosci 16:1037903. https://doi.org/10.3389/fncel.2022.1037903CrossRefPubMedPubMedCentral

103.

Wang Q, Han CL, Wang KL, Sui YP, Li ZB, Chen N, Fan SY, Shimabukuro M, Wang F, Meng FG (2020) Integrated analysis of exosomal lncRNA and mRNA expression profiles reveals the involvement of lnc-MKRN2-42:1 in the pathogenesis of Parkinson’s disease. CNS Neurosci Ther 26(5):527–537. https://doi.org/10.1111/cns.13277CrossRefPubMed

104.

Cao Z, Wu Y, Liu G, Jiang Y, Wang X, Wang Z, Feng T (2019) α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson’s disease. Neurosci Lett 696:114–120. https://doi.org/10.1016/j.neulet.2018.12.030CrossRefPubMed

105.

Rani K, Mukherjee R, Singh E, Kumar S, Sharma V, Vishwakarma P, Bharti PS, Nikolajeff F, Dinda AK, Goyal V, Kumar S (2019) Neuronal exosomes in saliva of Parkinson’s disease patients: A pilot study. Parkinsonism Relat Disord 67:21–23. https://doi.org/10.1016/j.parkreldis.2019.09.008CrossRefPubMed

106.

Fraser KB, Moehle MS, Daher JP, Webber PJ, Williams JY, Stewart CA, Yacoubian TA, Cowell RM, Dokland T, Ye T, Chen D, Siegal GP, Galemmo RA, Tsika E, Moore DJ, Standaert DG, Kojima K, Mobley JA, West AB (2013) LRRK2 secretion in exosomes is regulated by 14–3-3. Hum Mol Genet 22(24):4988–5000. https://doi.org/10.1093/hmg/ddt346CrossRefPubMedPubMedCentral

107.

Fraser KB, Rawlins AB, Clark RG, Alcalay RN, Standaert DG, Liu N Parkinson’s Disease Biomarker Program Consortium; West AB (2016) Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson’s disease. Mov Disord 16;31(10):1543–1550. https://doi.org/10.1002/mds.26686

108.

Chen Y, Xia K, Chen L, Fan D (2019) Increased interleukin-6 levels in the astrocyte-derived exosomes of sporadic amyotrophic lateral sclerosis patients. Front Neurosci 13:574. https://doi.org/10.3389/fnins.2019.00574CrossRefPubMedPubMedCentral

109.

Ivanova MV, Chekanova EO, Belugin BV, Dolzhikova IV, Tutykhina IL, Zakharova MN (2020) Exosomal angiogenin as a potential biomarker in amyotrophic lateral sclerosis. Neurochem J 16(5):723–735. https://doi.org/10.1134/S1819712420030058CrossRef

110.

Zhou Q, He L, Hu J, Gao Y, Shen D, Ni Y, Qin Y, Liang H, Liu J, Le W, Chen S (2022) Increased expression of coronin-1a in amyotrophic lateral sclerosis: a potential diagnostic biomarker and therapeutic target. Front Med 16(5):723–735. https://doi.org/10.1007/s11684-021-0905-yCrossRefPubMed

111.

Xu Q, Zhao Y, Zhou X, Luan J, Cui Y, Han J (2018) Comparison of the extraction and determination of serum exosome and miRNA in serum and the detection of miR-27a-3p in serum exosome of ALS patients. Intract Rare Dis Res 7(1):13–18. https://doi.org/10.5582/irdr.2017.01091CrossRef

112.

Banack SA, Dunlop RA, Cox PA (2020) An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral sclerosis/motor neuron disease. Open Biol 10(6):200116. https://doi.org/10.1098/rsob.200116CrossRefPubMedPubMedCentral

113.

Lo TW, Figueroa-Romero C, Hur J, Pacut C, Stoll E, Spring C, Lewis R, Nair A, Goutman SA, Sakowski SA, Nagrath S, Feldman EL (2021) Extracellular vesicles in serum and central nervous system tissues contain microRNA signatures in sporadic amyotrophic lateral sclerosis. Front Mol Neurosci 14:739016. https://doi.org/10.3389/fnmol.2021.739016CrossRefPubMedPubMedCentral

114.

Kim JA, Park C, Sung JJ, Seo DJ, Choi SJ, Hong YH (2023) Small RNA sequencing of circulating small extracellular vesicles microRNAs in patients with amyotrophic lateral sclerosis. Sci Rep 13(1):5528. https://doi.org/10.1038/s41598-023-32717-yCrossRefPubMedPubMedCentral

115.

Liu Y, Ding M, Pan S, Zhou R, Yao J, Fu R, Yu H, Lu Z (2023) MicroRNA-23a-3p is upregulated in plasma exosomes of bulbar-onset ALS patients and targets ERBB4. Neuroscience 524:65–78. https://doi.org/10.1016/j.neuroscience.2023.05.030CrossRefPubMed

116.

Saucier D, Wajnberg G, Roy J, Beauregard AP, Chacko S, Crapoulet N, Fournier S, Ghosh A, Lewis SM, Marrero A, O’Connell C, Ouellette RJ, Morin PJ (2019) Identification of a circulating miRNA signature in extracellular vesicles collected from amyotrophic lateral sclerosis patients. Brain Res 1708:100–108. https://doi.org/10.1016/j.brainres.2018.12.016CrossRefPubMed

117.

Banack SA, Dunlop RA, Stommel EW, Mehta P, Cox PA (2022) miRNA extracted from extracellular vesicles is a robust biomarker of amyotrophic lateral sclerosis. J Neurol Sci 442:120396. https://doi.org/10.1016/j.jns.2022.120396CrossRefPubMed

118.

Cheng YF, Gu XJ, Yang TM, Wei QQ, Cao B, Zhang Y, Shang HF, Chen YP (2023) Signature of miRNAs derived from the circulating exosomes of patients with amyotrophic lateral sclerosis. Front Aging Neurosci 15:1106497. https://doi.org/10.3389/fnagi.2023.1106497CrossRefPubMedPubMedCentral

119.

Ananbeh H, Novak J, Juhas S, Juhasova J, Klempir J, Doleckova K, Rysankova I, Turnovcova K, Hanus J, Hansikova H, Vodicka P, Kupcova SH (2022) Huntingtin Co-isolates with small extracellular vesicles from blood plasma of TgHD and KI-HD pig models of Huntington’s disease and human blood plasma. Int J Mol Sci 23(10):5598. https://doi.org/10.3390/ijms23105598CrossRefPubMedPubMedCentral

120.

Zhang T, Ma S, Lv J, Wang X, Afewerky HK, Li H, Lu Y (2021) The emerging role of exosomes in Alzheimer’s disease. Ageing Res Rev 68:101321. https://doi.org/10.1016/j.arr.2021.101321CrossRefPubMed

121.

Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K (2006) Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A 103(30):11172–11177. https://doi.org/10.1073/pnas.0603838103CrossRefPubMedPubMedCentral

122.

Li TR, Wang XN, Sheng C, Li YX, Li FZ, Sun Y, Han Y (2019) Extracellular vesicles as an emerging tool for the early detection of Alzheimer’s disease. Mech Ageing Dev 184:111175. https://doi.org/10.1016/j.mad.2019.111175CrossRefPubMed

123.

Hao Y, Su C, Liu X, Sui H, Shi Y, Zhao L (2022) Bioengineered microglia-targeted exosomes facilitate Aβ clearance via enhancing activity of microglial lysosome for promoting cognitive recovery in Alzheimer’s disease. Biomater Adv 136:212770. https://doi.org/10.1016/j.bioadv.2022.212770CrossRefPubMed

124.

Jahangard Y, Monfared H, Moradi A, Zare M, Mirnajafi-Zadeh J, Mowla SJ (2020) Therapeutic effects of transplanted exosomes containing miR-29b to a rat model of Alzheimer’s disease. Front Neurosci 14:564. https://doi.org/10.3389/fnins.2020.00564CrossRefPubMedPubMedCentral

125.

Zhai L, Shen H, Sheng Y, Guan Q (2021) ADMSC Exo-MicroRNA-22 improve neurological function and neuroinflammation in mice with Alzheimer’s disease. J Cell Mol Med 25(15):7513–7523. https://doi.org/10.1111/jcmm.16787CrossRefPubMedPubMedCentral

126.

Yemula N, Njoku P, Takyi J (2022) The second brain in Parkinson’s disease: fact or fantasy? Neural Regen Res 17(8):1737–1738. https://doi.org/10.4103/1673-5374.332144CrossRefPubMedPubMedCentral

127.

Gopar-Cuevas Y, Duarte-Jurado AP, Diaz-Perez RN, Saucedo-Cardenas O, Loera-Arias MJ, Montes-de-Oca-Luna R, Rodriguez-Rocha H, Garcia-Garcia A (2021) Pursuing multiple biomarkers for early idiopathic Parkinson’s disease diagnosis. Mol Neurobiol 58(11):5517–5532. https://doi.org/10.1007/s12035-021-02500-zCrossRefPubMed

128.

Duan Y, Wang Y, Liu Y, Jin Z, Liu C, Yu X, Chen K, Meng D, Xi J, Fang B (2023) Circular RNAs in Parkinson’s disease: reliable biological markers and targets for rehabilitation. Mol Neurobiol 60(6):3261–3276. https://doi.org/10.1007/s12035-023-03268-0CrossRefPubMed

129.

Izco M, Blesa J, Schleef M, Schmeer M, Porcari R, Al-Shawi R, Ellmerich S, de Toro M, Gardiner C, Seow Y, Reinares-Sebastian A, Forcen R, Simons JP, Bellotti V, Cooper JM, Alvarez-Erviti L (2019) Systemic exosomal delivery of shrna minicircles prevents Parkinsonian pathology. Mol Ther 27(12):2111–2122. https://doi.org/10.1016/j.ymthe.2019.08.010CrossRefPubMedPubMedCentral

130.

Ren X, Zhao Y, Xue F, Zheng Y, Huang H, Wang W, Chang Y, Yang H, Zhang J (2019) Exosomal DNA aptamer targeting α-synuclein aggregates reduced neuropathological deficits in a mouse Parkinson’s disease model. Mol Ther Nucleic Acids 17:726–740. https://doi.org/10.1016/j.omtn.2019.07.008CrossRefPubMedPubMedCentral

131.

Li Q, Wang Z, Xing H, Wang Y, Guo Y (2021) Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson’s disease. Mol Ther Nucleic Acids 23:1334–1344. https://doi.org/10.1016/j.omtn.2021.01.022CrossRefPubMedPubMedCentral

132.

He S, Wang Q, Chen L, He YJ, Wang X, Qu S (2023) miR-100a-5p-enriched exosomes derived from mesenchymal stem cells enhance the anti-oxidant effect in a Parkinson’s disease model via regulation of Nox4/ROS/Nrf2 signaling. J Transl Med 21(1):747. https://doi.org/10.1186/s12967-023-04638-xCrossRefPubMedPubMedCentral

133.

Peng H, Li Y, Ji W, Zhao R, Lu Z, Shen J, Wu Y, Wang J, Hao Q, Wang J, Wang W, Yang J, Zhang X (2022) Intranasal administration of self-oriented nanocarriers based on therapeutic exosomes for synergistic treatment of Parkinson’s disease. ACS Nano 16(1):869–884. https://doi.org/10.1021/acsnano.1c08473CrossRefPubMed

134.

Geng Y, Long X, Zhang Y, Wang Y, You G, Guo W, Zhuang G, Zhang Y, Cheng X, Yuan Z, Zan J (2023) FTO-targeted siRNA delivery by MSC-derived exosomes synergistically alleviates dopaminergic neuronal death in Parkinson’s disease via m6A-dependent regulation of ATM mRNA. J Transl Med 21(1):652. https://doi.org/10.1186/s12967-023-04461-4CrossRefPubMedPubMedCentral

135.

Sharma V, Nikolajeff F, Kumar S (2023) Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases. Transl Neurodegener 12(1):7. https://doi.org/10.1186/s40035-023-00339-zCrossRefPubMedPubMedCentral

136.

Richards D, Morren JA, Pioro EP (2021) Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. In: Araki T, (ed). Amyotrophic Lateral Sclerosis [Internet]. Brisbane (AU): Exon Publications; 2021. Chapter 2. https://doi.org/10.36255/exonpublications.amyotrophiclateralsclerosis.diagnosticdelay

137.

Miguez A, Gomis C, Vila C, Monguió-Tortajada M, Fernández-García S, Bombau G, Galofré M, García-Bravo M, Sanders P, Fernández-Medina H, Poquet B, Salado-Manzano C, Roura S, Alberch J, Segovia JC, Allen ND, Borràs FE, Canals JM (2023) Soluble mutant huntingtin drives early human pathogenesis in Huntington’s disease. Cell Mol Life Sci 80(8):238. https://doi.org/10.1007/s00018-023-04882-wCrossRefPubMedPubMedCentral

138.

Ananbeh H, Vodicka P, Kupcova SH (2021) Emerging roles of exosomes in Huntington’s disease. Int J Mol Sci 22(8):4085. https://doi.org/10.3390/ijms22084085CrossRefPubMedPubMedCentral

139.

Byun S, Lee M, Kim M (2022) Gene therapy for Huntington’s disease: the final strategy for a cure? J Mov Disord 15(1):15–20. https://doi.org/10.14802/jmd.21006

140.

Zhang L, Wu T, Shan Y, Li G, Ni X, Chen X, Hu X, Lin L, Li Y, Guan Y, Gao J, Chen D, Zhang Y, Pei Z, Chen X (2021) Therapeutic reversal of Huntington’s disease by in vivo self-assembled siRNAs. Brain 144(11):3421–3435. https://doi.org/10.1093/brain/awab354CrossRefPubMedPubMedCentral

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Exosomes for neurodegenerative diseases: diagnosis and targeted therapy

Abstract

Purpose of Review

Recent Findings

Summary